PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer
- PMID: 20460918
- DOI: 10.1159/000282095
PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer
Abstract
The tumor suppressor PTEN is a protein/phosphoinositide phosphatase regulating the PI3K/Akt signaling pathway and is mutated or deleted in a variety of human cancers, including hepatocellular carcinoma (HCC). Accumulating evidence indicates that alterations of PTEN expression and activity in hepatocytes are common and recurrent molecular events associated with liver disorders of various etiologies including obesity, the metabolic syndrome, hepatitis B virus/hepatitis C virus infection and abusive alcohol consumption. Genetic and molecular studies, particularly in the context of non-alcoholic fatty liver disease (NAFLD), support a critical role for PTEN in hepatic insulin sensitivity and the development of steatosis, steatohepatitis and fibrosis. PTEN mutations/deletion or low PTEN expression are also associated with diverse liver malignancies, suggesting a critical role for PTEN in hepatic cancers. This review provides an overview of the current knowledge on pathological dysregulations of PTEN expression/activity in the liver with obesity and the metabolic syndrome, and the role of this enzyme in the development of non-alcoholic fatty liver disease and hepatocellular carcinoma.
Copyright 2010 S. Karger AG, Basel.
Similar articles
-
Understanding the tumor suppressor PTEN in chronic alcoholism and hepatocellular carcinoma.Adv Exp Med Biol. 2015;815:173-84. doi: 10.1007/978-3-319-09614-8_10. Adv Exp Med Biol. 2015. PMID: 25427907 Review.
-
Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets.Hepatology. 2011 Jul;54(1):38-49. doi: 10.1002/hep.24340. Hepatology. 2011. PMID: 21465511
-
PTEN at the crossroad of metabolic diseases and cancer in the liver.Ann Hepatol. 2008 Jul-Sep;7(3):192-9. Ann Hepatol. 2008. PMID: 18772845 Review.
-
Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice.J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S96-S100. doi: 10.1111/j.1440-1746.2006.04665.x. J Gastroenterol Hepatol. 2007. PMID: 17567478
-
[Tumor suppressor gene PTEN and non-alcoholic steatohepatitis (NASH)].Nihon Rinsho. 2005 Aug;63(8):1475-83. Nihon Rinsho. 2005. PMID: 16101243 Review. Japanese.
Cited by
-
Distinct changes in serum metabolites and lipid species in the onset and progression of NAFLD in Obese Chinese.Comput Struct Biotechnol J. 2024 Jan 20;23:791-800. doi: 10.1016/j.csbj.2024.01.007. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 38318437 Free PMC article.
-
Advances in the pharmacological effects and molecular mechanisms of emodin in the treatment of metabolic diseases.Front Pharmacol. 2023 Oct 31;14:1240820. doi: 10.3389/fphar.2023.1240820. eCollection 2023. Front Pharmacol. 2023. PMID: 38027005 Free PMC article. Review.
-
Scutellarein regulates the PTEN/AKT/NFκB signaling pathway to reduce pirarubicin related liver inflammation.Int J Mol Med. 2023 Jul;52(1):55. doi: 10.3892/ijmm.2023.5258. Epub 2023 May 26. Int J Mol Med. 2023. PMID: 37232353 Free PMC article.
-
MiR-22 Deficiency Fosters Hepatocellular Carcinoma Development in Fatty Liver.Cells. 2022 Sep 14;11(18):2860. doi: 10.3390/cells11182860. Cells. 2022. PMID: 36139435 Free PMC article.
-
mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease.Int J Mol Sci. 2022 Aug 16;23(16):9196. doi: 10.3390/ijms23169196. Int J Mol Sci. 2022. PMID: 36012464 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
